Abstract
Aims: To determine prognostic factors for overall survival in patients with metastatic gastric cancer (mGC).
Methods: A retrospective descriptive study on patients with stage IV gastric cancer in the Oncology Center of Hue Central Hospital, Viet Nam, from 2015 to 2020. Before initiating treatment, demographic, clinical, and laboratory features as well as treatment methods were documented. The Kaplan–Meier test was used to estimate overall survival. Prognostic factors of survival were identified using the Cox model.
Results: There were a total of 167 patients, with a median age of 58. The majority of patients had BMI under 18.5 kg/m² (64.1%) and KPS above 80 (86.8%) prior to treatment. The most common clinical symptom was epigastric pain (73.7%). 86.2% of patients had serum albumin levels below 35 g/L. 64.0% of patients underwent palliative surgery, including 69.2% who had gastrectomy. The chemotherapy rate was 59.9%, with 93.0% multidrug cytotoxic regimens. The median survival was 11 months. By using multivariate analysis, serum albumin (95%CI: 1.055–3.190, p = 0.032), palliative surgery (95%CI: 0.407–0.873, p = 0.008), and multidrug chemotherapy regimens (95%CI: 0.424–0.920, p = 0.017) were independent prognostic factors.
Conclusion: Patients with stage IV gastric cancer have poor overall survival at 11 months. Lower serum albumin, palliative surgery, and doublet/triplet chemotherapy were four independent prognostic factors.
References
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209-249.
Patel TH, Cecchini M. Targeted Therapies in Advanced Gastric Cancer. Curr Treat Options Oncol. 2020;21(9):70.
Sasahara M, Kanda M, Kodera Y. Update on molecular biomarkers for diagnosis and prediction of prognosis and treatment responses in gastric cancer. Histol Histopathol. 2021;36(8):817-832.
Stewart C, Chao J, Chen YJ, Lin J, Sullivan MJ, Melstrom L, et al. Multimodality management of locally advanced gastric cancer-the timing and extent of surgery. Transl Gastroenterol Hepatol. 2019;442.
Tsai CY, Lin TA, Huang SC, Hsu JT, Yeh CN, Chen TC, et al. Is Adjuvant Chemotherapy Necessary for Patients with Deficient Mismatch Repair Gastric Cancer?-Autophagy Inhibition Matches the Mismatched. Oncologist. 2020;25(7):e1021-e1030.
Trần Vĩnh Thọ, Trần Thiện Trung. Kết quả hóa trị ung thư dạ dày giai đoạn tiến xa. Tạp chí Y học TP Hồ Chí Minh. 2014;18(1):589-597.
Lee JS, Kim YS, Kim EY, Jin W. Prognostic significance of CT-determined sarcopenia in patients with advanced gastric cancer. PLoS One. 2018;13(8):e0202700.
Tomita Y, Moldovan M, Chang Lee R, Hsieh AH, Townsend A, Price T. Salvage systemic therapy for advanced gastric and oesophago-gastric junction adenocarcinoma. Cochrane Database Syst Rev. 2020;11(11):CD012078.
Jeong O, Park YK, Choi WY, Ryu SY. Prognostic significance of non-curative gastrectomy for incurable gastric carcinoma. Ann Surg Oncol. 2014;21(8):2587-93.
Kinoshita J, Yamaguchi T, Moriyama H, Fushida S. Current status of conversion surgery for stage IV gastric cancer. Surg Today. 2021;51(11):1736-1754.
| Published | 20-05-2023 | |
| Fulltext |
|
|
| Language |
|
|
| Issue | No. 86 (2023) | |
| Section | Original article | |
| DOI | 10.38103/jcmhch.86.2 | |
| Keywords | Gastric cancer; metastatic stage; prognostic factors. |
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Copyright (c) 2023 Journal of Clinical Medicine Hue Central Hospital